Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Target Lowered at Barclays

Phathom Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Barclays lowered its Phathom Pharmaceuticals price target from $14 to $10 but maintained an “overweight” rating; the new target implies about 81.8% upside from the stock’s current price.
  • Analyst sentiment remains broadly positive: MarketBeat reports a “Moderate Buy” consensus and an average price target of $19.67, with eight Buy and one Strong Buy ratings among the 11 analysts cited.
  • PHAT opened at $5.50, near its 12-month low of $5.01, and below its 50-day and 200-day moving averages of $6.82 and $9.96, respectively.
  • Five stocks we like better than Phathom Pharmaceuticals.

Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) had its target price cut by investment analysts at Barclays from $14.00 to $10.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has an "overweight" rating on the stock. Barclays's price objective would indicate a potential upside of 81.82% from the stock's current price.

A number of other equities research analysts have also issued reports on the stock. Guggenheim cut their price objective on shares of Phathom Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a report on Friday, July 31st. Leerink Partners assumed coverage on shares of Phathom Pharmaceuticals in a research report on Wednesday, September 9th. They set a "market perform" rating and a $10.00 price objective on the stock. Craig Hallum reissued a "buy" rating and issued a $15.00 target price on shares of Phathom Pharmaceuticals in a report on Wednesday, October 21st. Jefferies Financial Group restated a "buy" rating and set a $16.00 target price on shares of Phathom Pharmaceuticals in a research report on Wednesday, October 14th. Finally, Citigroup restated a "buy" rating on shares of Phathom Pharmaceuticals in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $19.67.

View Our Latest Stock Analysis on Phathom Pharmaceuticals

Phathom Pharmaceuticals Price Performance

Shares of PHAT opened at $5.50 on Wednesday. The business's 50 day moving average is $6.82 and its 200 day moving average is $9.96. Phathom Pharmaceuticals has a 12-month low of $5.01 and a 12-month high of $18.31.

Hedge Funds Weigh In On Phathom Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in PHAT. Allworth Financial LP lifted its position in Phathom Pharmaceuticals by 31.0% in the third quarter. Allworth Financial LP now owns 13,684 shares of the company's stock worth $100,000 after buying an additional 3,241 shares during the last quarter. Entropy Technologies LP bought a new position in Phathom Pharmaceuticals during the third quarter valued at $537,000. Pathstone Holdings LLC increased its position in Phathom Pharmaceuticals by 16.7% during the third quarter. Pathstone Holdings LLC now owns 17,500 shares of the company's stock valued at $128,000 after acquiring an additional 2,500 shares during the last quarter. Kornitzer Capital Management Inc. KS bought a new position in Phathom Pharmaceuticals during the third quarter valued at $460,000. Finally, Catalys Pacific LLC increased its position in Phathom Pharmaceuticals by 26.0% during the third quarter. Catalys Pacific LLC now owns 1,882,039 shares of the company's stock valued at $13,739,000 after acquiring an additional 388,185 shares during the last quarter. 99.01% of the stock is owned by hedge funds and other institutional investors.

Phathom Pharmaceuticals Company Profile

(Get Free Report)

Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Founded in 2018, the company is based in Florham Park, New Jersey, and concentrates its commercial activities on the U.S. market. Its primary product is Voquezna (vonoprazan), an acid blocker used to treat certain conditions involving gastroesophageal reflux disease (GERD), including erosive esophagitis and heartburn associated with non-erosive GERD. Vonoprazan is also used with antibiotics to treat Helicobacter pylori infection.

Further Reading

Analyst Recommendations for Phathom Pharmaceuticals (NASDAQ:PHAT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Phathom Pharmaceuticals Right Now?

Before you consider Phathom Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.

While Phathom Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines